Context Therapeutics Inc. (CNTX)
NASDAQ: CNTX · Real-Time Price · USD
1.525
-0.105 (-6.44%)
Nov 21, 2024, 10:41 AM EST - Market open
Context Therapeutics Employees
Context Therapeutics had 5 employees as of December 31, 2023. The number of employees decreased by 4 or -44.44% compared to the previous year.
Employees
5
Change (1Y)
-4
Growth (1Y)
-44.44%
Revenue / Employee
n/a
Profits / Employee
-$6,030,416
Market Cap
114.37M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 5 | -4 | -44.44% |
| Dec 31, 2022 | 9 | 8 | 800.00% |
| Dec 31, 2020 | 1 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Cibus | 183 |
| Repare Therapeutics | 179 |
| Zomedica | 144 |
| Compugen | 68 |
| Candel Therapeutics | 42 |
| Cardiff Oncology | 32 |
| Avalo Therapeutics | 19 |
CNTX News
- 14 days ago - Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results - GlobeNewsWire
- 4 weeks ago - Context Therapeutics to Participate in Upcoming Investor Conferences in November - GlobeNewsWire
- 5 weeks ago - Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting - GlobeNewsWire
- 2 months ago - Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors - GlobeNewsWire
- 3 months ago - Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results - GlobeNewsWire
- 4 months ago - Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations - GlobeNewsWire
- 4 months ago - Context Therapeutics: Acquired Asset CT-95 Could Enhance T-Cell Engager Pipeline - Seeking Alpha
- 4 months ago - Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95 - GlobeNewsWire